Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Low dose dinaciclib enhances doxorubicin-induced senescence in myeloma RPMI8226 cells by transformation of the p21 and p16 pathways.
|
30405800 |
2018 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our results indicate that ANRIL may be involved in melphalan-mediated apoptosis via down-regulating p14ARF and subsequent p53, and that the rs2151280 polymorphism may be a potential prognostic biomarker for relapse in melphalan-treated MM patients.
|
28150872 |
2017 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This is the second case report of germline mutation of CDKN2A being associated with myeloma.CDKN2A is a stabiliser of p53.
|
29110637 |
2017 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma.
|
27363682 |
2016 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Subjects carrying the KCNQ1rs2237892T allele or the CDKN2A-2Brs2383208G/G, IGF1rs35767T/T and MADDrs7944584T/T genotypes had a significantly increased risk of MM (odds ratio (OR)=1.32-2.13) whereas those carrying the KCNJ11rs5215C, KCNJ11rs5219T and THADArs7578597C alleles or the FTOrs8050136A/A and LTArs1041981C/C genotypes showed a significantly decreased risk of developing the disease (OR=0.76-0.85).
|
26099684 |
2015 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The cyclin-dependent kinase inhibitor 1 (CDKN2B or p15(INK4B) ) gene lies adjacent to the tumor suppressor gene, cyclin-dependent kinase inhibitor 2 (CDKN2A), and is frequently mutated and deleted in a wide variety of tumors, including MM.
|
25382971 |
2014 |
Multiple Myeloma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
The current meta-analysis confirms and reinforces existing findings that p15 (INK4b) and p16 (INK4a) promoter methylation may be closely implicated in the pathogenesis of MM.
|
24908414 |
2014 |
Multiple Myeloma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
Prevalence of p16 methylation and prognostic factors in plasma cell myeloma at a single institution in Korea.
|
23301219 |
2013 |
Multiple Myeloma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Moreover low-expression CDKN2A group showed time-to-progression benefit in newly diagnosed patients (remission was 20.8 ± 3.6 months for 'low' and 8.4 ± 2.7 months for 'high' expressed group, p<0.0001) as well as in whole studied cohort of MM patients (remission was 20.8 ± 2.8 months for 'low' and 9.8 ± 1.1 months for 'high' expressed group, p<0.0001).
|
23831116 |
2013 |
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We investigated the methylation status of p16 and its association with common cytogenetic changes, clinicolaboratory findings, and survival in MM.
|
20721556 |
2011 |
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our findings suggest methylation of TP73, ARF, p15 INK4B , and p16 INK4A as early events in the pathogenesis and development of plasma cell disorders; meanwhile, SOCS-1 methylation would be an important step in the clonal evolution from MGUS to MM.
|
19727727 |
2010 |
Multiple Myeloma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The Sumo-conjugating enzyme Ube2I, the Sumo-ligase PIAS1, and the Sumo-inducer ARF were elevated in MM patient samples and cell lines.
|
19965618 |
2010 |
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Herein, we report the identification of Snk/Plk2 as a novel methylated gene in MM and show that methylation is not influenced in this CpG island or in that of a previously described methylated gene, CDKN2A, in MM.
|
21067440 |
2010 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We have tested whether CpG methylation of both CDKN2A and TP73 occurs in 45 individuals with multiple myeloma (24 male and 21 female, mean age 66.4 years) and in 4 patients (2 male and 2 female, mean age 61.7 years) with Waldenström's macroglobulinemia.
|
19423161 |
2009 |
Multiple Myeloma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
The QMSP analyses showed that PTGS2 (100.0%), SFN (100.0%), CDKN2B (90.2%), CDH1 (88.2%), ESR1 (72.5%), HIC1 (70.5%), CCND2 (62.7%), DCC (45.1%) and TGFbetaR2 (39.2%) are frequently hypermethylated in MM while aberrant methylation of RARbeta (16.6%), MGMT (12.5%), AIM1 (12.5%), CDKN2A (8.3%), SOCS1 (8.3%), CCNA1 (8.3%) and THBS1 (4.1%) are rare events.
|
19548309 |
2009 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We also found no association between p16 methylation and the main cytogenetic categories, although it was more common among patients with 17p13.1 deletions (p53 locus), a genetic progression event in MM.
|
16840723 |
2007 |
Multiple Myeloma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
Of the putative tumour suppressor genes in the DAP kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway, only DAP kinase is frequently methylated in MM, which is associated with gene silencing and might be of prognostic significance. p14 and Apaf-1 were not methylated in MM.
|
17557868 |
2007 |
Multiple Myeloma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
In 32 cases of multiple myeloma and 19 cases of MGUS, significantly more frequent methylation of p16 (p = 0.001), SHP1 (p< or =0.001) and E-cadherin (p< or =0.001) genes was found in multiple myeloma than in MGUS.
|
17213358 |
2007 |
Multiple Myeloma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
As regards p16 methylation, we confirmed a high prevalence of p16 methylation (40%) in patients affected by MM and demonstrated that MTHFR 677CC is associated with a higher prevalence of p16 hypermethylation.
|
16541270 |
2006 |
Multiple Myeloma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The association of increased p14ARF/p16INK4a and p15INK4a gene expression with proliferative activity and the clinical course of multiple myeloma.
|
17043023 |
2006 |
Multiple Myeloma
|
0.500 |
PosttranslationalModification
|
disease |
LHGDN |
As regards p16 methylation, we confirmed a high prevalence of p16 methylation (40%) in patients affected by MM and demonstrated that MTHFR 677CC is associated with a higher prevalence of p16 hypermethylation.
|
16541270 |
2006 |
Multiple Myeloma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
Therefore, p16 methylation seems to have no correlation with angiogenesis and VEGF expression, neither with overall and event-free survival in MM patients.
|
15863274 |
2005 |
Multiple Myeloma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
This data favours the importance of p16 methylation on cell cycle regulation in multiple myeloma.
|
16166769 |
2005 |
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
CTD_human |
These results indicate that methylation of p16 gene is essential important in the pathogenesis of MM and may provide a new diagnostic technique and drug target for the treatment of MM.
|
16008847 |
2005 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The methylation patterns of the genes p16(INK4a) (p16), tissue inhibitor of metalloproteinase 3 (TIMP3), p15(INK4b) (p15), E-cadherin (ECAD), death-associated protein kinase (DAPK), p73, RAS-association domain family 1A (RASSF1A), p14, O(6)-methylguanine DNA methyltransferase (MGMT), and retinoid acid receptor beta2 (RARbeta) were determined in patients with monoclonal gammopathy of undetermined significance (MGUS; n = 29), smoldering multiple myeloma (SMM; n = 5), multiple myeloma (MM; n = 113), or plasma cell leukemia (PCL; n = 7) by methylation-specific polymerase chain reaction analysis.
|
15197802 |
2004 |